Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95–111

Article  PubMed  Google Scholar 

Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D et al (2008) Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248(1):84–96

Article  PubMed  Google Scholar 

Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73(2):198–222

Article  PubMed  Google Scholar 

Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149(6):565–574

Article  PubMed  Google Scholar 

Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A et al (2020) Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg 155(9):823–831

Article  PubMed  Google Scholar 

Mason MC, Massarweh NN, Tzeng CD, Chiang YJ, Chun YS, Aloia TA et al (2021) Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol 28(11):6725–6735

Article  PubMed  Google Scholar 

Sutton TL, Billingsley KG, Walker BS, Enestvedt CK, Dewey EN, Orloff SL et al (2021) Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg 221(6):1182–1187

Article  PubMed  Google Scholar 

Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X et al (2023) Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunol Immunother 72(11):3717–3726

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q et al (2020) Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer 8(2):e001240

Article  PubMed  PubMed Central  Google Scholar 

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853–1865

Article  PubMed  Google Scholar 

Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1(8):EVIDoa2200015

Article  PubMed  Google Scholar 

ClinicalTrials.gov, Durvalumab or placebo in combination with gemcitabine/cisplatin in patients with 1st line advanced biliary tract cancer (TOPAZ-1) (TOPAZ-1), https://clinicaltrials.gov/study/NCT03875235. Accessed June 20, 2024

The U. S. Food and drug administration (2022) FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer. Accessed 20 Jun 2024

Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH et al (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 7(6):522–532

Article  PubMed  Google Scholar 

Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT et al (2024) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 9(8):694–704

Article  PubMed  Google Scholar 

Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V et al (2024) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25(5):626–635

Article  CAS  PubMed  Google Scholar 

Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y et al (2021) Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 22(3):175–183

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhang W, Wang H, Hu B, Wang Z, Lu S (2021) Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: a case report. Front Immunol 12:744571

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Luo C, Zhang ZY, Zhang BX, Chen XP (2023) Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: a case report and literature review. Front Immunol 13:1079342

Article  PubMed  PubMed Central  Google Scholar 

Nara S, Ioka T, Ogawa G, Kataoka T, Sano Y, Esaki M et al (2023) Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT). J Clin Oncol 41:TPS621–TPS621

Article  Google Scholar 

Buettner S, Koerkamp BG, Ejaz A, Buisman FE, Kim Y, Margonis GA et al (2017) The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-a multi-institutional analysis. J Surg Oncol 115(3):312–318

Article  CAS  PubMed  Google Scholar 

McCluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, McClelland HR et al (2002) Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55(1):27–31

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans AJ (2018) Treatment effects in prostate cancer. Mod Pathol 31(S1):S110–S121

Article  PubMed  Google Scholar 

Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40(2):127–132

Article  CAS  PubMed  Google Scholar 

Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID (2021) Tumour budding in solid cancers. Nat Rev Clin Oncol 18(2):101–115

Article  PubMed  Google Scholar 

Tanaka M, Yamauchi N, Ushiku T, Shibahara J, Hayashi A, Misumi K et al (2019) Tumor budding in intrahepatic cholangiocarcinoma: a predictor of postsurgery outcomes. Am J Surg Pathol 43(9):1180–1190

Article  PubMed  Google Scholar 

Agostini-Vulaj D, Cates JMM, Bratton LE, Gonzalez RS (2021) Increasing tumor budding in cholangiocarcinoma is associated with decreased disease-specific survival. Hum Pathol 111:75–83

Article  PubMed  Google Scholar 

Budau KL, Sigel CS, Bergmann L, Lüchtenborg AM, Wellner U, Schilling O et al (2022) Prognostic impact of tumor budding in intrahepatic cholangiocellular carcinoma. J Cancer 13(8):2457–2471

Article  PubMed  PubMed Central  Google Scholar 

Lohneis P, Sinn M, Klein F, Bischoff S, Striefler JK, Wislocka L et al (2018) Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Br J Cancer 118(11):1485–1491

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stögbauer F, Beck S, Ourailidis I, Hess J, Poremba C, Lauterbach M et al (2023) Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer. Br J Cancer 128(12):2295–2306

Article  PubMed  PubMed Central  Google Scholar 

Jain D, Chopp WV, Graham RP (2021) Protocol for the examination of resection specimens from patients with primary carcinoma of the colon and rectum. Available at: https://documents.cap.org/protocols/ColoRectal_4.3.0.0.REL_CAPCP.pdf. Accessed June 15, 2024

Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K et al (2013) Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 26(2):295–301

Article  CAS  PubMed  Google Scholar 

Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127(2):385–394

Article  PubMed